1. It's like a startup trying to be the next Biogen for brain disorders, but specifically pioneering intranasal drug delivery to tackle difficult conditions like brain cancer and Parkinson's.

2. Imagine a company similar to an early-stage Moderna or BioNTech, but instead of mRNA vaccines, they're developing nasal spray-delivered drugs to treat challenging brain cancers and Parkinson's disease.

Major Products of NeOnc Technologies (NTHI):

• NEO100: A purified form of perillyl acid (POH) administered intranasally for treating recurrent malignant gliomas, malignant skull-based meningiomas, and as a drug delivery vehicle for other therapies like levodopa for Parkinson's disease.
• NEO212: A covalently conjugated molecule combining temozolomide with perillyl alcohol, currently in a Phase I/II trial for oral administration to treat primary and secondary brain tumors, with future development for intranasal application.

```html

Based on the provided background information, NeOnc Technologies (NTHI) is a clinical-stage biopharmaceutical company. The company is currently focused on developing novel drug delivery methods and drug candidates for intracranial malignancies. Their lead products, NEO100 and NEO212, are in various stages of clinical trials (Phase I, Phase IIa) or preclinical development.

The company explicitly states:

• "Currently, none of our product candidates have been approved for sale in the United States or elsewhere."
• "We have no commercial products nor do we have a sales or marketing infrastructure."

Therefore, NeOnc Technologies does not currently have any major customers, as it does not yet have any approved or commercialized products available for sale to other companies or individuals.

```

null

Amir F. Heshmatpour, Chief Executive Officer, Executive Chairman, and President
Amir F. Heshmatpour is the Executive Chairman and President of NeOnc Technologies Holdings, Inc. where he drives the company's mission to transform the treatment of brain cancers. He has over 25 years of executive and board leadership experience. In 2005, he founded AFH Holding & Advisory LLC, his single-family office, through which he has led more than $6 billion in transactions across multiple industries, with a focus on biotech and healthcare. He acquired NeOnc in 2023 and assumed the presidency in 2025, and was appointed CEO in November 2025. Previously, he founded and served as Chairman and CEO of Metrophone Telecommunications, which completed 17 acquisitions and grew annual revenues to over $100 million.

Keithly Garnett, Chief Financial Officer
Keithly Garnett serves as the Chief Financial Officer for NeOnc Technologies Holdings, Inc. He directly owns a significant number of shares in the company and indirectly holds additional shares through HCWG LLC, where he is a beneficial owner.

Dr. Thomas C. Chen, MD, PhD, Founder, Chief Medical Officer, and Chief Scientific Officer
Dr. Thomas Chen is the founder of NeOnc Technologies. He transitioned from the CEO role to focus exclusively on his positions as Chief Medical Officer and Chief Scientific Officer, and remains a member of the Board of Directors. This transition allows him to dedicate his full attention to accelerating clinical trials and driving the scientific advancements of NeOnc's drug candidates.

Dr. Josh Neman, PhD, Chief Clinical Officer
Dr. Josh Neman is the Chief Clinical Officer at NeOnc Technologies Holdings, Inc.

David Choi, Chief Accounting Officer
David Choi was appointed as Chief Accounting Officer, effective March 12, 2026. In this role, he is responsible for overseeing the company's accounting, financial reporting, internal controls, and corporate governance functions. Mr. Choi is a CPA with over a decade of public-company accounting and controls experience from previous roles at Blythe Global Advisors, Grant Thornton, and Ernst & Young.

Key Risks to NeOnc Technologies (NTHI)

1. Clinical Trial Failure and Regulatory Approval Risk: NeOnc Technologies is a clinical-stage biopharmaceutical company with no currently approved products for sale. The success of the company is entirely dependent on the successful completion of ongoing and planned clinical trials (e.g., Phase IIa for NEO100, Phase I/II for NEO212, planned Phase I for intranasal NEO100 with levodopa) and obtaining regulatory approvals from agencies like the FDA. The background explicitly states that without successful clinical trials and regulatory approvals, the company cannot market and sell its products.
2. Commercialization and Market Entry Risk: Even upon successful regulatory approval, NeOnc Technologies faces significant risks in commercializing its products. The company currently has no commercial products and lacks a sales or marketing infrastructure. Building this infrastructure, establishing market presence, and competing effectively in the specialized and challenging brain cancer treatment market will be a substantial undertaking.
3. Patient Enrollment and Trial Execution Risk: The company has experienced challenges and made adjustments regarding patient enrollment for its NEO100 trials, specifically related to the limited population of IDH1,2 mutant Grade IV astrocytoma patients, which necessitated expanding the trial to include Grade III IDH1,2 mutant astrocytomas. While this adjustment aims to expedite the trial process, it highlights the inherent difficulties and potential delays associated with recruiting specific patient populations for specialized clinical trials, which can impact timelines and resource allocation.

null

null

Here are 3-5 expected drivers of future revenue growth for NeOnc Technologies (NTHI) over the next 2-3 years:

1. Accelerated Clinical Development and Expanded Patient Population for NEO100 in High-Grade Astrocytomas: The inclusion of recurrent Grade III IDH1,2 mutant astrocytoma patients in the Phase IIa trial for NEO100 significantly expands the target patient population. This strategic enrollment change is projected to expedite the trial process, with a readout for Phase II studies potentially delivered by the end of 2024, advancing the original timeline by a full year.
2. Initiation and Progress of NEO100 Clinical Trial for Malignant Skull-Based Meningioma: NeOnc launched a Phase IIa trial (NEO 100-02) in July 2023 for intranasal NEO100 in patients with malignant skull-based meningioma. This new indication addresses a patient population with limited effective treatment options and difficult-to-access tumors, representing a potential new market opportunity for NEO100.
3. Advancement of NEO212 into Phase I/II Clinical Trials for Primary and Secondary Brain Tumors: The company's second lead product, NEO212, began a Phase I/II trial in the fourth quarter of 2023. This trial administers oral NEO212 to patients with primary brain tumors (malignant gliomas) and secondary brain tumors (brain metastases), representing a new drug candidate entering human testing with the potential to address a broad range of intracranial malignancies.
4. Expansion of NEO100 into Parkinson's Disease as a Drug Delivery Vehicle: NeOnc is planning a Phase I clinical trial for intranasal NEO100 mixed with levodopa (L-DOPA) for patients with Parkinson's disease. This initiative expands NEO100's potential application beyond oncology into a new therapeutic area, offering a distinct pathway for future revenue generation if successful.

null